Cyclin Pas1/PHO80 Domain Containing 1 (CNPPD1): A Potential Drug Target and Biomarker

Target Name: CNPPD1

NCBI ID: G27013

CNPPD1

Cyclin Pas1/PHO80 Domain Containing 1 (CNPPD1): A Potential Drug Target and Biomarker

Cyclin Pas1/PHO80 domain containing 1 (CNPPD1) is a protein that plays a crucial role in the regulation of cell cycle progression in various organisms, including humans. The discovery of CNPPD1 as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for various diseases.

Molecular Background

CNPPD1, also known as cyclin D1, is a 28-kDa protein that is localized to the N-terminus of the alpha-tubulin protein. It is composed of a 165 amino acid residue long alpha-helical domain and a 155 amino acid residue long carboxy-terminal domain. The alpha-helical domain is responsible for the protein's stability and functions as a binding site for various nucleotides, including microtubules and transcription factors.

PHO80, a protein that contains a PHD-like domain, was identified as a potential interaction partner of CNPPD1. The PHD-like domain is known for its ability to form a covalent complex with various transition metals, including gold, which is thought to play a role in the regulation of protein stability and function.

Expression and Functions

CNPPD1 is highly expressed in various tissues, including brain, heart, and muscle. It is also expressed in various cell types, including cancer cells, and has been shown to be involved in various cellular processes, including cell growth, differentiation, and the regulation of cell cycle progression.

In addition to its role in cell cycle regulation, CNPPD1 has also been shown to play a role in various signaling pathways, including the regulation of cell adhesion, angiogenesis, and inflammation. For example, studies have shown that CNPPD1 can interact with various signaling molecules, including TGF-β1, PDGF-尾, and NF-kappa-B.

Drug Target Potential

The potential drug target for CNPPD1 is its role in cell cycle regulation and its involvement in various signaling pathways. Drugs that can inhibit CNPPD1's activity or modulate its expression levels have the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to targeting CNPPD1 is to inhibit its activity with small molecules that can inhibit the binding of CNPPD1 to microtubules or other proteins. Such compounds have been shown to have therapeutic potential in various diseases, including neurodegenerative disorders and cancer.

Another approach to targeting CNPPD1 is to modulate its expression levels. This can be achieved through various methods, including genetic modification, RNA interference, and protein knockdown. Mice lacking for CNPPD1 have been shown to have reduced levels of CNPPD1 and improved survival in various models of cancer.

Biomarker Potential

CNPPD1 has the potential to serve as a biomarker for various diseases. Its involvement in cell cycle regulation and various signaling pathways makes it an attractive candidate for the development of diagnostic tests for various diseases.

For example, CNPPD1 levels can be used as a marker for cancer, as increased levels of CNPPD1 have been observed in various types of cancer. Additionally, CNPPD1 levels can be used as a marker for neurodegenerative disorders, as decreased levels of CNPPD1 have been observed in various neurodegenerative disorders.

Conclusion

In conclusion, CNPPD1 is a protein that plays a crucial role in the regulation of cell cycle progression and has the potential to serve as a drug target or biomarker for various diseases. Its involvement in various signaling pathways makes it an attractive candidate for targeting with small molecules or modulating its expression levels. Further research is needed to fully understand the role of CNPPD1 in

Protein Name: Cyclin Pas1/PHO80 Domain Containing 1

The "CNPPD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNPPD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets